Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination
Cancer Immunology, Immunotherapy, 05/14/2012De Vleeschouwer S et al.
This HGG–IMMUNO recursive partitioning analysis (RPA) classification is able to predict overall survival in a large group of adult patients with a relapsed malignant glioma, treated with re–operation and postoperative adjuvant DC vaccination in the HGG–IMMUNO–2003 cohort comparison trial. The model appears useful for prognostic patient counseling for patients participating in dendritic cell (DC) vaccination trials. A substantial number of long–term survivors after relapse are seen in class I to III, but not in class IV patients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.